As the first next-generation PA inhibitor targeting influenza virus RNA polymerase developed domestically in China with fully independent global intellectual property rights, Jikeshu employs a " one-dose full course with long-lasting effects" administration regimen, providing a uniquely Chinese treatment solution—"one dose to ease"—in the fight against influenza. The successful approval of the adolescent indication will better address the differentiated medication needs of influenza patients across various age groups, delivering a convenient new treatment option for adolescents.

Since its launch, Jikeshu has earned recognition for its technological innovation and clinical value, having been included as a recommended treatment for both influenza A and influenza B in the Expert consensus on the rational use of antiviral drugs for influenza(2025 edition) and the Clinical practice guidelines for the treatment and prophylaxis of influenza in China (2025 edition). It has also been selected for the inaugural Jiangsu Province Innovative Drug and Device Product Catalog, laying a solid foundation for its clinical application and broader adoption.

In recent years, JumpCan Pharmaceutical has leveraged its dual-engine strategy of hospital-based and out-of-hospital channels, forming a short-, mid-, and long-term product portfolio through "mergers and acquisitions + in-house R&D + product in-licensing," with the goal of building a leading integrated pharmaceutical commercialization platform. JumpCan holds exclusive promotion and sales rights for Jikeshu in mainland China and has established a strategic partnership with Zenshine Pharmaceuticals covering product registration, manufacturing, promotion, channel management, and commercial sales. Following the approval of Jikeshu for the adult indication last year, the company has leveraged its extensive channel expertise to actively drive presence across hospitals, chain pharmacies, and online pharmaceutical platforms, enhancing patient access to the medication.

The approval of the adolescent indication represents a key opportunity to expand Jikeshu's market reach. JumpCan Pharmaceutical will maximize its channel advantages to accelerate full-scale commercialization and benefit a broader population of influenza patients, safeguarding public health. Going forward, JumpCan will continue to uphold a clinical-value-driven strategy, deepening its expertise in the core therapeutic areas of Pediatrics, Respiratory, and Gastroenterology, while accelerating its expansion into Dermatology and Cardiovascular fields. Through sustained innovation driven by "innovative drugs + new pipelines," the company will enrich its product portfolio and deliver more substantial clinical innovations in response to market expectations—contributing JumpCan's strength to advancing high-quality development of the pharmaceutical industry and supporting the Healthy China initiative.